An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease

Cognitive Impairment Clinical Trial

Official title:

Phase III Study of Sodium Oligo-mannurarate (GV-971) Capsule on Mild to Moderate Alzheimer Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02293915
• Other study ID #: 971-III
• Status: Completed
• Phase: Phase 3
• Start date: April 1, 2014
• Est. completion date: September 28, 2018

Study information

• Verified date: October 2018
• Source: Shanghai Greenvalley Pharmaceutical Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to determine the efficacy and safety of Sodium Oligo-mannurarate (GV-971) in 36-week treatment of mild to moderate Alzheimer's disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 818
• Est. completion date: September 28, 2018
• Est. primary completion date: June 29, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Aged 50-85 years (inclusive), no gender limitation;

2. Female subjects should be postmenopausal women (menopause >24 weeks), surgically sterilized women or women of child bearing age who agree to take effective contraceptive measures during the trial. Women of child bearing age and women less than 24 weeks from menopause must undergo urine pregnancy test in screening period and result must be negative;

3. Subjects have received education in primary school and above and are able to complete protocol specified cognitive ability test and other tests;

4. Impaired memory for at least 12 months, with a tendency of progressive aggravation;

5. Meet diagnostic criteria of probable AD according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) (1984);

6. Patients with mild to moderate disease, i.e. 11 =total MMSE score =26 (for subjects with primary school education, 11 =total MMSE score =22);

7. Total Hachinski Ischemia Scale (HIS) score =4 ;

8. Total Hamilton Depression Scale/17-item (HAMD) score =10;

9. In screening, cranial MRI plain scan and oblique coronal hippocampus scan must be performed, lacunar infarction lesions with a diameter larger than 2 cm =2, without lacunar infarction lesion in vital sites, such as thalamus, hippocampus, entorhinal cortex, paraolfactory cortex, cortex and other subcortical gray matter nuclei; MRI shows highest possibility of Alzheimer's disease (medial temporal lobe atrophy visual rating scale MTA grade =2);

10. Neurological examination shows no significant sign;

11. Subjects should have stable, reliable caregivers, or at least have frequent contact with caregivers (at least 4 days every week, at least 2 h every day), and caregivers will help patients in participation in this study. Caregivers must accompany subjects to participate in study visits and have sufficient interaction and communication with subjects, so as to provide valuable information on NPI, ADCS-ADL, CIBIC-plus scales.

12. Before implementation of any protocol related procedure or examination, subjects must sign the written informed consent form. If subjects can not sign due to limited cognition, legal guardians should sign on behalf of subjects and meanwhile, legal guardians should also sign the informed consent form.

Exclusion Criteria:

1. Participate in another clinical trial within 30 days prior to initiation of this study;

2. Pregnant or nursing women;

3. Dementia due to other causes: vascular dementia, central nervous system infection (e.g. AIDS, syphilis), Creutzfeldt-Jakob disease, Huntington's chorea, Parkinson's disease, dementia with Lewy bodies, traumatic dementia, other physical and chemical factors (e.g. drug poisoning, alcoholism, carbon monoxide poisoning), significant physical illness (e.g. hepatic encephalopathy, pulmonary encephalopathy), intracranial occupying lesion (e.g. subdural hematoma, brain tumor), endocrine disorders (e.g. thyroid disease, parathyroid disease) and dementia caused by vitamin or other factors;

4. Previous nervous system disorders (including stroke, optic neuromyelitis, Parkinson's disease, epilepsy);

5. Abnormal laboratory values: liver function (ALT, AST) > 1.5 times of upper limit of normal, Cr > 1.5 times of upper limit of normal, white blood cell count, platelet, hemoglobin below the lower limit of normal, blood glucose >1.5 times of upper limit of normal;

6. In screening, systolic blood pressure =160 mmHg or <90 mmHg, or diastolic blood pressure =100 mmHg or <60 mmHg;

7. Unstable or severe cardiac, pulmonary, hepatic, renal or hematopoietic disease (including unstable angina, uncontrolled asthma, active gastric bleeding and cancer), after 10 min rest, resting heart rate <55 bpm;

8. Visual or hearing disorder, preventing completion of neuropsychological test and scale evaluation;

9. In screening, MRI examination shows significant focal lesions, more than 2 lacunar infarction lesions with a diameter >2 cm, lacunar infarction lesions in vital sites, such as thalamus, hippocampus, entorhinal cortex, paraolfactory cortex, cortex and other subcortical gray matter nuclei; Fazekas scale for white matter lesions at = grade 3;

10. Alcohol abuse or drug abuse;

11. Patients with psychosis, including severe depression;

12. Patients who are using drugs for Alzheimer's disease which can not be stopped;

13. Use of heparin, Propylene Glycol Mannurate Sulfate or Alginric Sodium Diester within 3 weeks prior to screening;

14. Inability to take trial drugs according to prescription, previous non-compliance with prescription or possibility of non-compliance with study treatment in the trial;

15. Investigators consider subjects can not complete this study;

16. Subjects in the phase II trial of the study drug;

17. Subjects are investigators participating in this study or their direct relatives, staff of Quintiles (Shanghai) or Shanghai Greenvalley Pharmaceutical Co., Ltd. or their direct relatives.

Related Conditions & MeSH terms

• Alzheimer Disease
• Cognitive Dysfunction
• Cognitive Impairment
• Mild to Moderate Alzheimer Disease

Intervention

Drug:
• Sodium oligo-mannurarate 900mg
sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
• Placebo
simulant of sodium oligo-mannurarate capsule

Locations

Country	Name	City	State
China	Beijing	Beijing	Beijing
China	Changsha	Changsha	Hunan
China	Sichuan	Chengdu	Sichuan
China	Chongqing	Chongqing	Chongqing
China	Fujian	Fuzhou	Fujian
China	Guangzhou	Guangzhou	Guangdong
China	Hangzhou	Hangzhou	Zhejiang
China	Jinan	Jinan	Shandong
China	Nanjing	Nanjing	Jiangsu
China	Shanghai	Shanghai	Shanghai
China	Suzhou	Suzhou	Jiangsu
China	Tianjin	Tianjin	Tianjin
China	Wenzhou	Wenzhou	Zhejiang
China	Wuhan	Wuhan	Hubei
China	Xi'an	Xi'an	Shanxi
China	Yangzhou	Yangzhou	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Greenvalley Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement of Alzheimer's Disease Assessment Scale-cognitive subscale(ADAS-cog)/12 of sodium oligo-mannurarate capsule		36 weeks
Secondary	Improvement of Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) of sodium oligo-mannurarate capsule		36 weeks
Secondary	Improvement of Alzheimer's Disease Cooperative Study/Activities of Daily(ADCS-ADL) of sodium oligo-mannurarate capsule		36 weeks
Secondary	Improvement of Neuropsychiatric Inventory(NPI) of sodium oligo-mannurarate capsule		36 weeks
Secondary	Glucose metabolism of bilateral temporoparietal cortex	Obtained by Positron Emission Tomography in two sites.	36 weeks